Biotech Daily

Monday June 3, 2024

Daily news on ASX-listed biotechnology companies

*** MAY BDI-40 RECORD HIGH - UP 7%, ASX200 UP 0.5%, BIG CAPS DOWN 1%**

*** TODAY: ASX UP, BIOTECH EVEN: SYNTARA UP 10%; ATOMO DOWN 7%**

*** IMMUTEP TO RAISE $100m; TRADING HALT**

*** BCAL 'COMMITMENTS' FOR $10.5m PLACEMENT**

*** ADALTA OPTIONS RAISE $1.9m**

*** CORRECTION: AMPLIA THERAPEUTICS**

*** QUEENSLAND UNI, EMORY UNI TO OPEN $32m VACCINE CENTRE**

*** MCRI LICENCES RV3-BB ROTAVIRUS VACCINE TO INCEPTA**

*** CLINUVEL SCRAPS EU SCENESSE ADOLESCENT EPP APPLICATION**

*** TELIX: TLX250-CDx FDA BIOLOGICS APPLICATION FOR KIDNEY CANCER**

*** IMMUTEP PHASE III EFTI, KEYTRUDA, COMBO LUNG CANCER TRIAL**

*** RESONANCE COMPLETES TRIALSWEST PURCHASE**

*** ENLITIC COMMERCIALIZES ENSIGHT 2.0**

*** MAYNE PHARMA WINS SWISS KAPANOL APPROVAL**

*** ISLAND MODELS 'IDEAL SINGLE ISLA-101 PHASE II DOSE'**

*** INOVIQ 'EXOSOMES KILL BREAST CANCER CELLS', IN-VITRO**

*** ONCOSIL TREATS 200th PANCREATIC CANCER DEVICE PATIENT**

*** IMAGION VOTES REMUNERATION REPORT 2nd STRIKE, BOARD SPILL**

*** ANATARA 4.5m CHAIR, DIRECTOR OPTIONS EGM**

*** STUART MORRIS, SACAVIC TAKE 16% OF ADALTA**

*** PERCHERON APPOINTS DR CATHRYN CLARY CHIEF MEDICAL ADVISOR**

MARKET REPORT

The Australian stock market was up 0.77 percent on Monday June 3, 2024, with the ASX200 up 59.3 points to 7,761.0 points. Fifteen of the Biotech Daily Top 40 stocks were up, 16 were down, seven traded unchanged and two were untraded.

Syntara was the best, up 0.2 cents or 10 percent to 2.2 cents, with 1.9 million shares traded; followed by Percheron up 9.9 percent to 8.9 cents, with 2.8 million shares traded. Prescient climbed 4.4 percent; Clarity, Compumedics, Dimerix, Medadvisor and Polynovo rose more than two percent; Emvision, Next Science, Opthea, Proteomics and SDI were up one percent or more; with CSL, Pro Medicus and Telix up by less than one percent.

Atomo led the falls, down 0.2 cents or 6.7 percent to 2.8 cents, with 495,833 shares traded; followed by Neuren down 6.3 percent to $20.27 with 670,561 shares traded. Avita, Clinuvel, Cynata, Imugene, Nova Eye and Starpharma fell four percent or more; Alcidion, Medical Developments and Micro-X lost more than three percent; 4D Medical and Curvebeam shed more than two percent; Orthocell was down 1.4 percent; with Cochlear, Cyclopharm, Mesoblast and Resmed down by less than one percent.

BIOTECH DAILY TOP 40 INDEX (BDI-40)

The Biotech Daily Top 40 Index (BDI-40) continued its record-breaking run, up a further 7.2 percent in May to a collective market capitalization of $30,700 million, compared to the benchmark ASX200 up 0.5 percent to 7,702 points (see charts below).

For the year to May 31, 2024, the BDI-40 was up 51.6 percent and the ASX200 improved 8.6 percent.

The three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) slipped a further 0.8 percent in May to a collective market capitalization of $201,581 million. The record high was $215,852 million on August 31, 2021

CSL's 0.6 percent rise to $134,499 million failed to compensate for Resmed's 4.4 percent fall to $46,129 million and Cochlear down a further 1.6 percent to $20,953 million from its February record high. The three Big Caps were down 4.7 percent for the year to May 31.

The BDI-40 had 19 companies up, with 10 up by more than 10 percent; and 21 down, with nine down by more than 10 percent.

Pro Medicus added a further $904 million to the index, up 7.8 percent to $12,538 million; while Telix improved $286 million or 5.6 percent to $5,259 million.

The other big radio-pharmaceutical company, Clarity, was May's best, adding $710 million or 81.6 percent to $1,580 million.

From a much lower base, Amplia was up 58.3 percent to $19 million, followed by Cynata (57.9%), Dimerix (47.8%), Medadvisor (46.7%), Syntara (26.3%) Universal Biosensors (22.9%), Percheron (17.7%), Mesoblast (12.1%) and Avita (11.2%).

Imugene led the falls, down $147 million or 23.1 percent to $490 million, followed by Resonance (21.6%), Opthea (17.8%), Actinogen (17.0%), Next Science (15.6%), Prescient (14.3%), Emvision (13.4%), Nova Eye (12.5%) and Proteomics (11.2%).

Cannabis Corner lost a further 13.8 percent in May, down 46.4 percent for the year, with five companies down, led by Zelira losing 37.5 percent to a market capitalization of $5 million and six unchanged. The only marijuana company to improve was Emyria which has been more focussed on MDMA, up $5 million or 26.3 percent to $24 million.

The Nasdaq Biotechnology Index (NBI) was up 5.7 percent in May, to 4,401 points, and up 8.1 percent for the year. Three Australian companies that moved to the Nasdaq for "better valuations": Bionomics, Incannex and Kazia, continued to fall in May, down 18.75 percent; 5.6 percent and 14.3 percent, respectively. Eyepoint (formerly Psivida) fell 40.9 percent to $837 million - a long way from its February $2 billion valuation. Brisbane's Protagonist recovered 8.9 percent to $2,478 million and Redhill with Australian assets was up 4.8 percent to $22 million.

Outside the BDI-40, Argenica, Aroa, Arovella, Botanix, EBR, Imricor, Mach7, Neurotech, Optiscan, Race and Recce are all vying for promotion.

BDI-40 v ASX200 Jun 30, 2006 to May 31, 2024- Adjusted



Big Caps $m (Cochlear, CSL, Resmed) May 31, 2019 – May 31, 2024



IMMUTEP

Immutep says it expects to raise $100.2 million at 38 cents a share in a fully-underwritten $72 million placement and $28.2 million one-for-16 institutional and retail rights offer.
Immutep said the placement issue price was a 13.3 percent discount to the 30-day volume weighted average price.
The company said the non-renounceable entitlement offer consisted of a $16.9 million institutional component and an $11.3 million retail component.
Immutep said $60 million of the funds raised would be used to begin a phase III lung cancer trial and continue its phase IIb head and neck cancer trial and phase II breast cancer trial, with $28 million for efti manufacturing and $12.2 million for working capital.
The company said Bell Potter was acting corporate advisor and underwriter to the capital raise as well as joint lead manager with Canaccord and Wilsons Corporate.
Immutep said the retail component of the entitlement offer had a record date of June 5, would open on June 7 and close on June 20, 2024.
Separately, the company requested a trading halt “until the earlier of such time as it makes an announcement to the market in relation to the outcome of the placement and the institutional component of the entitlement offer”.
Trading will resume on June 5, 2024, or on an earlier announcement.
Immutep last traded at 45 cents.

BCAL DIAGNOSTICS

Bcal says it has “firm commitments” to raise $10.5 million at 10 cents a share in a placement to institutional and sophisticated investors.
Bcal did not state the discount rate of the issue price, but Biotech Daily calculates it is a 42.85 percent discount to the 17.5 cent closing price on May 29, 2024.
The company said its directors and chief executive officer Shane Ryan intended to participate in the placement, subject to shareholder approval.
Bcal said the funds would be used for product research and development, expanding its clinical services laboratory with equipment and staff, Australian product launch in 2024 and US product launch in 2025 and general working capital.
The company said the raise was undertaken with support from Spark Plus and Pac Partners, with Mills Oakley acting as legal adviser.
Bcal fell three cents or 17.1 percent to 14.5 cents with 2.8 million shares traded.

ADALTA

Adalta says it has raised $1,877,109 million through the exercise of 62,570,306 options at 3.0 cents each, issued under last year’s placement and rights offer.
Last year, Adalta said it raised $3.15 million in a two-for-five, rights offer at 2.5 cents a share with one option for every two shares purchased (BD: Apr 28, May 25, 2023).
Today, the company said it issued 173,075,186 options as part of “private placements and entitlement offers”, and the exercise price was a 20 percent premium to the closing price on May 29, 2024.
Adalta said that $1.8 million of the options were raised from an investment made by an “entity associated with Stuart Morris”, one of its top five shareholders.
The company said it would use the funds for phase II trials of AD-214 for idiopathic pulmonary fibrosis and its Adcella therapies program, as well as change the timing of drawdowns from its $3.7 million New Life Sciences Capital and Meurs Group loans.
Adalta was up 0.2 cents or eight percent to 2.7 cents.

CORRECTION: AMPLIA THERAPEUTICS

Friday's edition said that Cytopia's 387 (Ojjaara or momelotinib) was arguably the second Australian-invented drug approved by the US Food and Drug Administration.
We believe it was the third after Biota's Relenza and Hatchtech's Xeglyze.
The mistake was made by the new Artificial Intelligence sub-editor, which has been reprogrammed.
Amplia was unchanged at seven cents.

UNIVERSITY OF QUEENSLAND

The University of Queensland says it has a partnership with Atlanta, Georgia's Emory University to open a research and development centre for vaccines, worth $32 million.
The University said the Queensland Emory Vaccine Centre (QEVC), would be based at its Brisbane campus and the $32 million included contributions was supported by the Queensland Government, Emory University and industry partners.
The University said the centre would bring together industry partners including Sanofi and Vaxxas "to accelerate the development of vaccines and their delivery".
The University of Queensland said the partnership was an extension of "a long-standing collaboration in drug discovery … through Uniquest's Queensland's Emory Drug Discovery Initiative and the Queensland Emory Development Alliance together with [the Queensland Institute of Medical Research] Berghofer".
The University's vice-chancellor Prof Deborah Terry said the centre would "fast-track the translation of vaccines into viable treatments to improve the lives of people".
"Once operational, the QEVC will house more than 80 researchers and create over 20 direct jobs, provide new teaching and learning opportunities to boost Queensland's skills pipeline and help to attract and retain talent," Prof Terry said.
"The focus will be to ensure a robust pipeline of vaccines and therapeutics moving from discovery to commercialization … getting more vaccines from the lab to the communities that need them," Prof Terry said.

MURDOCH CHILDRENS RESEARCH INSTITUTE

The Murdoch Children's Research Institute says it has non-exclusively licenced its RV3-BB vaccine for rotavirus to Dhaka, Bangladesh's Incepta Pharmaceuticals.
Based at Melbourne's Royal Children's Hospital, the Institute said RV3-BB was discovered in Melbourne by Prof Ruth Bishop, was adapted and developed from a naturally occurring human strain of rotavirus and offered early protection against dehydrating diarrhoea from birth.
The Institute said in Bangladesh more than two million babies were born each year, and "globally, rotavirus claims the lives of about 450,000 children under the age of five annually, making the need for accessible and effective vaccines urgent".
MCRI said the RV3-BB vaccine was "intended for neonatal or infant dosing schedules as part of routine expanded program on immunization vaccinations [and] has the potential to save hundreds of thousands of children's lives annually".
The Institute said the agreement marked "another milestone in its journey to reduce the impact of rotavirus, the most common cause of severe diarrhoea in infants and young children worldwide".
MCRI director of infection, immunity and global health Prof Andrew Steer said the collaboration was "a significant step forward in our mission to protect vulnerable children from the effects of rotavirus infection".

CLINUVEL PHARMACEUTICALS

Clinuvel says it has withdrawn its submission to expand marketing authorization for Scenesse to adolescents with erythropoietic protoporphyria (EPP) patients in Europe.
In 2022, Clinuvel said it had applied to the European Medicines Agency (EMA) to expand the Scenesse, or afamelanotide 16mg, label to include adolescent patients with erythropoietic protoporphyria light intolerance (BD: Sep 5, 2022).
Last year, the company said the EMA wanted more data for its application to expand Scenesse to 12-to-17-year-old EPP patients (BD: Sep 5, 2023).
Today, Clinuvel said the decision followed “two years of discussions” with the European Medicines Agency including a formal hearing with the Committee for Medicinal Products for Human Use.
The company said it provide comparative analyses of data from adolescent patients and adult patients to the EMA which showed “a consistent and beneficial benefit-risk profile of the drug in EPP patients to date”.
Clinuvel said “after continued dialogue between the company and the agency, the EMA opined that it would not know whether a benefit-risk profile of Scenesse for adolescent EPP patients was established”.
The company said it withdraw the application following the hearing and was “preparing a future submission containing additional data”.
Clinuvel chief scientific officer Dr Dennis Wright said “based on the benefit-risk profile of Scenesse in adult EPP patients seen over two decades, plus data generated in adolescent patients, and the lack of alternative treatments, we disagree with the EMA’s recommendation”.
“Hence, we will generate more data from the use of the drug in this population and will file again,” Dr Wright said.
Clinuvel fell 74 cents or 4.65 percent to $15.16 with 81,330 shares traded.

TELIX PHARMACEUTICALS

Telix says it has filed a US Food and Drug Administration (FDA) biologics licence application for its radio-diagnostic TLX250-CDx for clear cell renal cell carcinoma.
Last year, Telix said it had been granted a ‘breakthrough therapy’ rolling review process for TLX250-CDx, or Zircaix, allowing it to submit material and review required modules on a schedule agreed with the FDA (BD: Dec 19, 2023).
The company said the submission was based on its recent 300-patient, ‘Zircon’, phase III trial which met its primary and secondary endpoints, with 86 percent sensitivity and 87 percent specificity (BD: Nov 7, 2022).
Today, Telix said it had requested a priority review under the FDA’s breakthrough therapy designation which, if granted, would expedite the review time.
The company said, if approved, TLX250-CDx would be the first targeted radio-pharmaceutical imaging agent specifically for kidney cancer to be commercially available in the US and further built on its “successful urology imaging franchise”.
Telix chief development officer James Stonecypher said the submission represented “a significant milestone for Telix as we bring our breakthrough investigational kidney cancer imaging agent closer to market as a non-invasive diagnostic for patients”.
“We believe TLX250-CDx is a natural follow-on product to Illuccix as it is targeted at the same clinical stakeholders, the urologist and urologic oncologist, and leverages the proven commercial and distribution infrastructure developed through the launch of Illuccix,” Mr Stonecypher said.
Telix was up 10 cents or 0.6 percent to $18.25 with 1.9 million shares traded.

IMMUTEP

Immutep says it will conduct a 750-patient, phase III trial of eftilagimod alpha, or efti, for first line, non-small cell lung cancer with Keytruda and standard chemotherapy.
Immutep said it had a clinical trial agreement with Rahway, New Jersey's Merck and Co to supply pembrolizumab, or Keytruda for the trial.
The company said the trial would be a randomized, double-blind, controlled study to evaluate the combination of efti with Keytruda and standard-of-care chemotherapy compared to Keytruda and standard-of-care chemotherapy alone, or placebo.
Immutep said the 'all-comer' trial would assess squamous and non-squamous lung cancer patients "regardless of [programmed cell death ligand 1] expression".
The company said the endpoints of the trial were "progression-free and overall survival with a pre-specified futility boundary and a pre-planned interim analysis".
Immutep chief executive officer Marc Voigt said the company was "eager to build upon the meaningful impact that immunotherapy has brought to patients with [non-small cell lung cancer], one of the largest cancer indications globally".
Mr Voigt said the company hoped the trial would "confirm the clinical benefits that have been achieved with efti in combination with Keytruda".
"We are thankful for this significant commitment from Merck," Mr Voigt said.

RESONANCE HEALTH

Resonance says it has completed its acquisition of the Perth-based clinical trial and research centre Trialswest Pty Ltd for a total of $7.2 million.
In April, Resonance said it would acquire Trialswest for $4 million in up-front cash and a further $4 million in an earnout arrangement (BD: Apr 2, 2024).
Today, the company said the up-front payment was funded by its cash reserves and that it had secured a three-year, $3.2 million loan from National Australia Bank.
Resonance was unchanged at 6.4 cents.

ENLITIC

Enlitic says it has released its Ensight 2.0 medical imaging analyzer "18 months ahead of schedule" and has begun commercializing the product.
Enlitic said Ensight was used to generate "standardized study and series descriptions from pixel and metadata of medical images and deidentifies Protected Health Information (PHI) found in these images" for improving radiologist reporting workflows.
The company said Ensight 2.0 had expanded capabilities including its "Endex data standardization module and the Encog anonymization module into a unified software framework coupled with key infrastructural components required to deliver the planned common data model".
Enlitic was unchanged at 25 cents.

MAYNE PHARMA

Mayne says Switzerland has approved its generic 10mg and 200mg Kapanol morphine sulfate pentahydrate capsules for moderate to severe prolonged pain.
Mayne Pharma said Kapanol was approved by Switzerland's regulatory authority Swissmedic at 20mg, 50mg and 100mg doses, and the drug was exclusively licenced by Lipomed AG in Switzerland and other European territories.
Mayne Pharma fell three cents or 0.6 percent to $5.01 with 201,600 shares traded.

ISLAND PHARMACEUTICALS

Island says computer models of its single ascending dose study of ISLA-101 for dengue fever confirm a “predicted ideal single dose” for a phase II clinical study.
A chart in the Island announcement said that “Data modelling predicts 300mg/m^2 twice daily dose for phase II study”.
In April, Island said its 24-subject, single-ascending dose study showed a single dose of ISLA-101 achieved the required levels of blood concentration (BD: Apr 16, 2024).
Today, the company said the data “potentially obviates” the need to conduct its phase II trial at multiple doses, reducing the costs and resources associated with the trial.
Island said the modelling data would be submitted to the US Food and Drug administration with the study protocol for the phase II study, including an expansion from pure prophylactic focus to a therapeutic arm.
Island managing-director Dr David Foster said “this final piece of data from the dose escalation study confirms what we’ve seen and reported to date”.
“The results from this new modelling suggest that the blood concentration will increase upon repeat dosing, resulting in blood concentrations that exceed the concentration demonstrated to be effective in pre-clinical studies”, Dr Foster said.
Island fell 0.1 cents or 1.5 percent to 6.6 cents.

INOVIQ

Inoviq says a proof-of-concept study shows it has “successfully produced and isolated engineered exosomes … that target and kill breast cancer cells, in-vitro”.
Inoviq said its modified chimeric antigen receptor (CAR) protein expressing exosomes were isolated using its Exo-Ace technology, which “recovered more than 80 percent of exosomes from cell-conditioned media with over 95 percent purity”.
The company said that “when treated with these exosomes, 75 percent of breast cancer cells underwent cell death within 72 hours”.
Inoviq said that “based on these excellent results” it would progress its exosome therapeutics program, with a focus on immune-cell derived exosome therapeutics for metastatic breast and ovarian cancers.
Inoviq chief executive officer Dr Leearne Hinch said the results “highlight the potential of immune-cell derived exosomes as an effective cancer therapy and the potential for RNA drug-loaded exosome therapeutics”.
“The company is scaling its exosome production capacity using its Exo-Ace technology to isolate exosomes and advancing its immune cell-derived exosome program towards key preclinical in-vitro and in-vivo milestones for cancer starting [this year],” Ms Hinch said.
Inoviq chair David Williams said “exosomes released by immune cells have enormous potential as off-the-shelf therapeutics, with potential manufacturing, safety and efficacy advantages over autologous cell therapies for treatment of solid tumors.”
Inoviq was up 18.5 cents or 39.8 percent to 65 cents with 4.9 million shares traded.

ONCOSIL MEDICAL

Oncosil says it has treated the 200th unresectable, locally advanced, pancreatic cancer patient with its Oncosil single-use brachytherapy device for pancreatic tumors.
Oncosil said the treatment was conducted at the Royal Adelaide Hospital and was “a significant milestone”.
Oncosil was unchanged at half a cent with 5.2 million shares traded.

IMAGION BIOSYSTEMS

Imagion says its annual general meeting voted a remuneration report 'second strike', with 47.01 percent opposed and a spill resolution passed by 50.98 percent.
Last year, Imagion said its annual general meeting voted a remuneration report 'first strike' with 44,624,043 votes (25.20%) against (BD: May 25, 2023).
Under the Corporations Amendment (Improving Accountability on Director and Executive Remuneration) Act 2011 a company sustaining a vote of 25 percent or more against the remuneration report in two successive annual meetings is required to vote on a board spill and if passed, the directors must stand for re-election at a meeting within 90 days.
Today, the company said the report was opposed by 164,625 votes (47.01%) and the spill resolution was carried with 161,409 votes (50.98%) in favor; with the election of directors Michael Harsha and Mark Van Asten were opposed by more than 26 percent.
According to its most recent notice, Imagion had 32,646,551 shares on issues, meaning the votes against the remuneration report amounted to 0.5 percent of the company.
Imagion was in a suspension and last traded at 7.3 cents.

ANATARA LIFESCIENCES

Anatara says shareholders will vote to issue 2,500,000 options to chair Dr David Brookes and 1,000,000 options each to directors Nicholas Haslam and John Michailidis.
Anatara said its extraordinary general meeting would vote to issue the options to Dr Brookes, Mr Haslam and Mr Michailidis as part of its executive option plan and were exercisable at 10 cents each within four years from their vesting date.
The company said the options were in addition to Dr Brookes' $147,289 annual salary, Mr Michailidis' $133,251 yearly pay and Mr Haslam's $58,915 a year director fees.
Anatara said the meeting would vote to ratify the issue of placement shares, including shares to Dr Brookes and Michailidis, and ratify the issue of advisor options.
The meeting will be held online and at Thomson Geer, Level 7, 19 Gouger Street, Adelaide on July 5, 2024 at 12pm (ACST).
Anatara was untraded at 4.7 cents.

ADALTA

Stuart Morris, with Sacavic Pty Ltd, says he has increased his shareholding in Adalta from 33,862,999 shares (6.73%) to 97,441,722 shares (16.36%).
The Melbourne-based Mr Morris said that between December 4, 2023 and May 31, 2024 he acquired 4,720,882 shares on-market and off-market for $122,558, or 2.6 cents a share, and on June 3, 2024 he exercised 59,903,201 options for $1,797,096 or 3.0 cents each (see above).

PERCHERON THERAPEUTICS

Percheron says it has appointed Dr Cathryn Clary as a part-time chief medical advisor, effective immediately.
Percheron said Dr Clary had been head of US Medical at Pfizer, consulting chief medical officer at Solid Biosciences and had worked for Ipsen Biopharmaceuticals and Novartis.
The company said Dr Clary held a Bachelor of Arts from Pennsylvania's Bryn Mawr College, a Doctor of Medicine from the University of Missouri-Columbia and a Master of Business Administration from Newark's University of Delaware.
Percheron was up 0.8 cents or 9.9 percent to 8.9 cents with 2.8 million shares traded.

BIOTECH DAILY TOP 40 WITH MARKET CAPITALIZATION AT MAY 31, 2024

Company $Am	**May 31, 2023**	**Apr 30, 2024**	**May 31, 2024**
Cochlear	15,998	21,292	20,953
CSL	147,793	133,745	134,499
Resmed	47,679	48,252	46,129
BDI-20			
Avita	436	347	386
Clinuvel	924	754	759
Compumedics	30	46	43
Cyclopharm	188	165	155
Cynata	24	38	60
Genetic Signatures	84	130	136
Immutep	264	511	535
Impedimed	272	170	154
Medical Developments	74	41	37
Mesoblast	826	1,130	1,267
Nanosonics	1,518	885	824
Neuren	1,752	2,452	2,646
Nova Eye	50	64	56
Opthea	276	411	338
Polynovo	1,025	1,415	1,519
Pro Medicus	6,198	11,634	12,538
SDI	96	102	94
Starpharma	162	52	47
Syntara	39	19	24
Telix	3,725	4,973	5,259
Second 20			
4D Medical	263	235	231
Actinogen	84	88	73
Alcidion	120	72	78
Amplia	17	12	19
Atomo	17	20	19
Clarity	139	870	1,580
Curvebeam	87	61	58
Dimerix	23	184	272
Emvision	108	186	161
Imugene	707	637	490
Medadvisor	134	165	242
Micro-X	64	50	53
Next Science	108	90	76
Orthocell	72	81	76
Paradigm	240	94	87
Percheron	42	62	73
Prescient	65	42	36
Proteomics	117	143	127
Resonance	18	37	29
Universal Biosensors	54	35	43

* Biotech Daily editor, David Langsam, owns shares in Acrux, Actinogen, Alcidion, Alterity, Amplia, BTC Health, Clarity, Cochlear, Control Bionics, Cynata, Nanosonics, Neuren, Patrys, Pharmaxis, Polynovo, Telix, Volpara and non-biotech stocks. Through Australian Ethical Superannuation he has an indirect interest in other companies: **https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/.** These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au